Market Opportunity Nanologica leads in nanoporous silica for peptide drug purification, aligning with pharma manufacturers seeking cost reductions and productivity gains in insulin and GLP-1 analogue production. Potential sales focus: supply of silica purification media to CDMOs and biopharma manufacturers expanding peptide therapeutic portfolios.

Strategic Acquisition Recent acquisitions of Ardena Södertälje assets and the Syntagon facility indicate a strategic push into API manufacturing and CDMO capabilities. Sales opportunity: offer process optimization, custom silica formulations, and scale-ready purification media to integrate with their new API and manufacturing footprint.

Leadership Growth Upcoming CFO appointment signals possible financial scaling and governance strengthening. Sales angle: propose long-term supply arrangements, pricing models, and collaborative partnerships with clear procurement roadmaps to align with growing financial and operational ambitions.

Global Expansion Investments to acquire European API facilities suggest Nordic and European market expansion. Sales focus: expand regional sales, technical support, and regulatory-compliant materials for Europe-based peptide drug manufacturers and CDMOs seeking localized supply chains.

Financial Footprint Current revenue is under one million with a small employee base, indicating a high-growth, early-stage opportunity. Sales approach: target tier-1 and tier-2 pharmaceutical manufacturers and emerging biotech firms with scalable pilot-to-commercial silica purification solutions and attractive onboarding pilots.